Unified Protocol and Neuroticism: A Transdiagnostic Treatment Approach
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders, usually shortened to the Unified Protocol or UP, is an emotion-focused cognitive behavioral treatment designed for anxiety, depressive, and related emotional disorders. Neuroticism matters to the UP because the protocol was developed around shared vulnerabilities that cut across diagnoses, including a broad tendency toward frequent and intense negative emotional experience and maladaptive responses to those emotions. In contemporary personality science, however, neuroticism is a dimensional trait—not a psychiatric diagnosis and not a disease that treatment must “cure.”
The most important question is therefore narrower and more scientific: when adults with emotional disorders receive the UP, do validated measures of neuroticism change beyond ordinary symptom fluctuation? Randomized and longitudinal studies now provide a qualified yes. A secondary analysis of a 223-person randomized trial found lower neuroticism after UP than after diagnosis-specific cognitive behavioral therapy or waitlist, even after accounting for concurrent anxiety and depression changes (Sauer-Zavala et al., 2021). More recent intensive repeated-measure studies suggest that early score reductions can look state-like, whereas a fuller course of treatment may be needed before changes more clearly resemble trait-level change (Stumpp et al., 2024; Stumpp et al., 2026).
That evidence is clinically interesting, but it does not establish the UP as a generic personality treatment for anyone with a high neuroticism score. The strongest evidence comes from adults seeking treatment for emotional disorders. It also does not mean that symptom relief and personality change are interchangeable. The two can occur together, influence one another, and still require separate measurement and interpretation.
Unified Protocol and neuroticism: the short answer
The Unified Protocol appears capable of reducing measured neuroticism in some clinical samples, especially when treatment is sufficiently intensive and when the protocol directly targets patterns of responding to negative emotion. The best-supported interpretation is that neuroticism-related change can occur during UP treatment, and some evidence suggests that this change is not fully explained by simultaneous reductions in anxiety and depressive symptoms.
Three boundaries keep that conclusion accurate. First, neuroticism is a personality dimension. Higher neuroticism is associated with greater average vulnerability to internalizing psychopathology, but a high score does not diagnose generalized anxiety disorder, depression, obsessive-compulsive disorder, post-traumatic stress disorder, or any other condition. For the broader risk literature, see Neuroticism and Mental Health: Why the Trait Is a Transdiagnostic Risk Factor.
Second, a neuroticism score only has meaning inside a specific instrument, scoring method, and population. The major UP studies have not all used the same measure. A change on the Eysenck Personality Questionnaire Revised–Short Form is not numerically interchangeable with a change on the NEO Five-Factor Inventory, BFI-2 Negative Emotionality, an IPIP scale, or another instrument. For general score interpretation, see Neuroticism Test: What It Measures and How to Interpret Results.
Third, treatment can change symptoms, states, learned coping patterns, and trait measures on different time scales. A person can feel less anxious this week without showing durable personality change. Conversely, a repeated shift in how the person reacts to negative emotions may gradually alter the stable pattern captured by a trait measure. Distinguishing those levels is central to the modern UP literature.
What the Unified Protocol is
The Unified Protocol is a transdiagnostic cognitive behavioral intervention. “Transdiagnostic” means that the treatment is organized around processes shared across multiple disorders rather than around one diagnosis alone. The protocol was developed for emotional disorders in which intense negative emotion, avoidance, rigid threat-focused interpretations, and maladaptive emotion-driven behavior can maintain distress across conventional diagnostic boundaries.
The largest landmark equivalence trial randomized 223 adults with a principal anxiety disorder—panic disorder with or without agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, or social anxiety disorder—to the UP, a diagnosis-specific CBT protocol, or a waitlist condition. On the trial’s primary clinical outcome, the UP was statistically equivalent to the diagnosis-specific protocols, and treatment completion was higher in the UP condition (Barlow et al., 2017). This establishes that the UP is an evidence-based treatment for emotional disorders; it does not by itself establish personality change.
A later state-of-the-science review describes the UP as an emotion-focused CBT approach that targets core temperamental and regulatory features underlying emotional disorders, especially neuroticism and associated emotion dysregulation, while also emphasizing the need for more work in routine clinical settings and more heterogeneous populations (Farchione et al., 2024).
Earlier and broader outcome research also supports the protocol’s clinical efficacy. A randomized trial in a diagnostically heterogeneous anxiety sample found improvements in disorder severity, anxiety, depression, positive and negative affect, and functioning (Farchione et al., 2012). Meta-analyses have likewise found meaningful reductions in anxiety and depressive symptoms and improvements in emotion-regulation outcomes across UP studies (Sakiris & Berle, 2019; Carlucci et al., 2021). These symptom and process outcomes are relevant context, but they remain conceptually separate from evidence that the broad personality trait neuroticism itself changed.
What neuroticism means in this treatment literature
Neuroticism is a broad, continuous personality dimension describing individual differences in the tendency to experience negative emotions more frequently or intensely and to react strongly to perceived threat, frustration, uncertainty, or loss. In Big Five language, emotional stability is usually treated as the opposite pole. The BFI-2 uses the domain label Negative Emotionality, which overlaps strongly with neuroticism but is embedded in its own measurement model. The term negative affect often refers to unpleasant emotional experience at a state or shorter-term level and should not be treated as a synonym for the personality trait.
The general construct is reviewed in Neuroticism: What It Is in the Big Five Personality Model. A separate comparison of trait and affective-state language is available in Neuroticism vs Negative Affect: Trait, State, and Measurement. These distinctions matter because clinical studies sometimes measure related processes—negative affect, anxiety sensitivity, experiential avoidance, intolerance of uncertainty, or emotion regulation—without measuring a broad neuroticism domain directly.
Higher neuroticism is robustly associated with a range of common mental-health problems, especially internalizing disorders. That is why the trait can be described as a transdiagnostic vulnerability factor. A vulnerability factor changes average risk; it does not determine an individual outcome. Many people high in neuroticism never develop a psychiatric disorder, and many people with anxiety or depression are not extreme on every neuroticism measure.
Why the UP treats neuroticism as a transdiagnostic target
The UP is built around the idea that emotional disorders share patterns in how people experience and respond to strong emotions. The protocol therefore does not treat sadness, anxiety, anger, guilt, bodily arousal, or uncertainty as problems simply because they occur. It focuses on rigid, avoidant, or counterproductive responses that can make emotional experiences more disruptive and persistent.
In practice, core UP skills include understanding emotional experiences, mindful emotional awareness, cognitive flexibility, countering emotion-driven behaviors, and increasing tolerance of uncomfortable physical sensations. In one analysis of 88 UP participants from the major randomized trial, measures of these skills improved over treatment and skill changes were associated with anxiety-symptom improvement (Sauer-Zavala et al., 2021). Those findings support the idea that the protocol changes trainable responses to emotion.
This is also where neuroticism and emotion regulation intersect without becoming identical. Neuroticism concerns a broad dispositional tendency; emotion regulation concerns processes used to influence emotional experience and behavior. The UP may affect a trait partly by repeatedly changing the person’s habitual responses to emotional cues, but the mechanism is still an empirical question. For the broader construct boundary, see Neuroticism and Emotion Regulation: Strategies, Flexibility, and Distress.
The strongest randomized evidence that UP can change measured neuroticism
The 223-person trial
The most direct evidence comes from Sauer-Zavala and colleagues’ analysis of the randomized trial that compared the UP with established diagnosis-specific CBT protocols and a waitlist. The sample included 223 treatment-seeking adults with a principal anxiety disorder. Neuroticism was measured repeatedly alongside clinician-rated symptoms (Sauer-Zavala et al., 2021).
At week 16, participants assigned to the UP had significantly lower neuroticism scores than participants assigned to diagnosis-specific CBT, with an effect size of d = −0.32, and lower scores than the waitlist group, with d = −0.43. The between-treatment difference was therefore modest rather than dramatic. Its importance lies in the comparison: both active treatments improved clinical symptoms, while the UP showed a larger reduction on the neuroticism measure.
The authors also tested whether the neuroticism result disappeared after accounting for concurrent changes in anxiety and depression. The group differences remained. That analysis weakens a simple explanation in which neuroticism scores fell only because patients happened to feel less anxious or depressed at the time of assessment. It still does not prove that every observed score change was a permanent alteration of personality.
The measurement used was EPQR-S neuroticism
The trial measured neuroticism with the 12-item Neuroticism subscale of the Eysenck Personality Questionnaire Revised–Short Form, or EPQR-S. The parent inventory contains 48 items across Extraversion, Neuroticism, Psychoticism, and a Lie scale. In this study, respondents answered the neuroticism items yes or no; internal consistency across assessment points ranged from α = .63 to .77 (Sauer-Zavala et al., 2021).
That detail prevents a common interpretation error. The reported effect sizes refer to change on this Eysenck neuroticism scale in this clinical sample. They do not create a universal point reduction that can be applied to a NEO PI-R score, a NEO-FFI score, BFI-2 Negative Emotionality, an IPIP score, or an online percentile. Different instruments define and score the construct differently.
Why comparison with disorder-specific CBT matters
The same parent trial showed that the UP and diagnosis-specific CBT protocols produced equivalent improvement on the principal disorder severity outcome (Barlow et al., 2017). That creates an informative pattern: comparable symptom treatment does not necessarily imply identical movement in a broad personality measure.
The neuroticism analysis therefore supports a specific hypothesis rather than a sweeping superiority claim. The UP may engage neuroticism more directly than symptom-focused protocols because it deliberately targets cross-cutting emotional processes. The result does not show that the UP is globally “better than CBT,” because the UP itself is a CBT-based treatment and the parent trial found equivalent primary clinical outcomes.
State change versus trait change
A central challenge in personality-treatment research is the state-artifact problem. Neuroticism questionnaires ask about characteristic patterns, but self-report can still be influenced by current distress. Someone completing a trait measure during an acute depressive or anxious episode may endorse more negative-emotion items than the same person would after symptoms improve. A lower post-treatment score could therefore reflect symptom relief, durable trait change, or a mixture of both.
Trait change requires evidence that goes beyond a single pre-treatment and post-treatment comparison. Researchers can strengthen the inference by measuring neuroticism frequently, modeling within-person and between-person variance, controlling concurrent symptoms, examining temporal ordering, and testing whether change persists as treatment progresses or after treatment ends.
This distinction is especially important for the Unified Protocol because the treatment is expected to reduce symptoms and alter emotional responding at the same time. The scientific question is not whether the score moved. It is what kind of change the score represents.
What the 2024 intensive study adds
Stumpp, Southward, and Sauer-Zavala studied 38 adults meeting DSM-5 criteria for a primary emotional disorder who completed up to 12 weekly UP sessions. Neuroticism was measured before each session with the 12-item Neuroticism subscale of the NEO Five-Factor Inventory, or NEO-FFI-N, using five-point response options (Stumpp et al., 2024).
Their analyses suggested that neuroticism showed state-level change by session 6 and trait-level change by session 12. Within-person reductions in neuroticism were bidirectionally related to anxiety changes, while reductions in neuroticism predicted subsequent session-to-session reductions in depression. The authors interpreted the pattern as more nuanced support for a model in which neuroticism can itself become a treatment-relevant change process rather than merely mirroring symptoms.
The study is informative because it measured neuroticism repeatedly rather than only before and after treatment. It is also small. With 38 participants, it offers mechanistic evidence that should be integrated with the larger randomized trial rather than treated as a definitive estimate of treatment effect in all populations.
The instrument difference is again important. This study used NEO-FFI-N, whereas the 223-person trial used the EPQR-S neuroticism subscale. Both measure neuroticism, yet they are distinct instruments with different item content, response formats, score ranges, and psychometric traditions. Numerical scores should remain instrument-specific.
What the 2026 treatment-duration study adds
A newer randomized study examined 70 adults with an emotional disorder and varied both the sequencing of UP modules and treatment duration. Participants were randomized to a standard, strengths-prioritized, or deficits-prioritized module sequence and to either 6 or 12 sessions. The central question was when neuroticism changes and whether the sequence or length of treatment alters that trajectory (Stumpp et al., 2026).
During the first six sessions, neuroticism changes did not significantly differ between the brief and full-treatment conditions. After accounting for anxiety and depressive symptoms, there was no significant neuroticism reduction across those first six sessions. From sessions 7 through 12, participants continuing the full course showed significant reductions in neuroticism and greater change than the brief-treatment condition.
This pattern supports a clinically useful distinction between early improvement and more durable trait-like change. Brief treatment can produce movement in a neuroticism score, but some of that movement may be tied to changing state distress. A longer course may provide more repeated opportunities for new emotional-learning patterns to stabilize. The evidence does not establish a universal minimum number of sessions, and treatment length should not be prescribed from one study alone.
The finding also does not mean that six sessions are ineffective. Shorter treatment can still improve clinically important symptoms or skills. It means that the evidentiary standard for claiming personality-trait change is different from the standard for showing symptom relief.
How UP-related trait change may happen
The UP does not ask patients to become a different personality type. It trains repeated ways of approaching, observing, interpreting, and responding to emotional experiences. If those responses become habitual across situations, a broad trait measure may eventually register a more stable shift.
Understanding emotional patterns
Patients learn to identify relationships among triggers, appraisals, emotions, bodily sensations, and behavior. This can reduce the sense that emotional reactions are inexplicable or uncontrollable. Improved understanding is a skill outcome; a later change in a neuroticism score would be a separate trait outcome.
Mindful emotional awareness
The protocol trains present-focused, less judgmental attention to emotion. The goal is not to suppress negative emotion. It is to notice emotional experience without immediately escalating, escaping, or treating the emotion itself as dangerous.
Cognitive flexibility
UP work includes examining automatic appraisals and generating alternative interpretations. Repeated flexibility around threat and uncertainty can alter how often everyday situations trigger rigid negative predictions.
Countering emotion-driven behavior
Avoidance, reassurance seeking, withdrawal, checking, or other emotion-driven actions can provide immediate relief while maintaining fear or distress. The UP uses approach-oriented behavior to weaken these cycles.
Tolerance of physical sensations and emotional exposure
The protocol also addresses feared physical sensations and uses exposure to emotional experiences. The learning target is greater willingness and tolerance, not the elimination of normal emotional arousal.
Research on skill acquisition found improvements across UP skills and associations between skill changes and symptom change (Sauer-Zavala et al., 2021). These data make a process-based account plausible. They do not yet establish that any single skill is the causal mediator of durable neuroticism change.
What meta-analyses show—and what they do not show
Meta-analytic evidence supports the UP as a treatment for emotional disorders. Sakiris and Berle synthesized 15 studies with 1,244 participants and found substantial improvements across anxiety, depression, several disorder-specific symptom domains, emotion-regulation strategies, functioning, and quality of life (Sakiris & Berle, 2019). Carlucci and colleagues later analyzed 19 randomized trials and 13 uncontrolled pre-post studies comprising 2,183 participants and reported moderate-to-large combined effects for anxiety and depressive symptoms, with continued improvement at follow-up in the included literature (Carlucci et al., 2021).
Those meta-analyses strengthen the clinical evidence for the UP. They should not be converted into a meta-analytic claim that the protocol reliably changes neuroticism, because their primary pooled outcomes were symptoms and related clinical processes. The neuroticism-specific evidence base is smaller and comes from dedicated secondary analyses and newer repeated-measure trials.
This separation is essential for search questions such as “Does the Unified Protocol lower neuroticism?” A treatment can have a broad evidence base for emotional disorders while the evidence for a particular personality-trait outcome remains narrower.
How the broader psychotherapy literature changes the interpretation
For the broader personality-change evidence and the CBT-specific comparison literature, see Can Neuroticism Change? Personality Development, Therapy, and Evidence and CBT and Neuroticism: What the Evidence Shows.
Neuroticism was once often treated as too stable to be a realistic treatment target over ordinary clinical time frames. Modern intervention research has changed that picture. Roberts and colleagues reviewed 207 studies tracking personality-trait measures during interventions. Across an average intervention length of about 24 weeks, personality measures changed, with emotional stability showing the largest treatment-associated shift among the Big Five domains (Roberts et al., 2017).
The review also found that changes could persist beyond the treatment period and were not confined to one psychotherapy type. This makes it scientifically plausible that therapy can alter trait measures. It also means that UP-specific findings should be interpreted within a broader literature on personality plasticity rather than as proof that the UP uniquely discovered how to change personality.
A crucial methodological point remains: changes in trait scores can reflect genuine enduring personality change, changes in self-concept, reductions in psychiatric symptoms, changes in response style, or combinations of these. Better studies use repeated measurement, symptom controls, randomized comparisons, and follow-up to separate those possibilities.
Neuroticism-related constructs are not the same as neuroticism
Some UP studies examine constructs closely associated with neuroticism rather than the broad trait itself. For example, a randomized study of 39 adults with comorbid anxiety and depression who were already taking a stable, optimized SSRI dose compared UP plus SSRI with continued SSRI alone. The UP-plus-SSRI group improved on negative affect, anxiety sensitivity, experiential avoidance, and intolerance of uncertainty (Zemestani et al., 2022).
Those are relevant mechanisms and vulnerability markers. They are not interchangeable with a Big Five neuroticism score. Negative affect concerns unpleasant emotional experience; anxiety sensitivity concerns beliefs about anxiety-related sensations; experiential avoidance concerns efforts to avoid internal experiences; intolerance of uncertainty concerns difficulty with uncertain situations. A study can show change in all four without proving the same magnitude of change in a broad personality domain.
This distinction also protects against a common SEO simplification in which every emotion-related outcome is labeled “neuroticism.” Scientific writing should preserve the measurement model used in each study.
Does UP change neuroticism or only symptoms?
The most defensible answer in 2026 is that both can change, and the changes are related without being identical. The randomized neuroticism analysis found a UP advantage that remained after controlling concurrent anxiety and depression fluctuations (Sauer-Zavala et al., 2021). The repeated-measure study found different timing for state-like and trait-like neuroticism change (Stumpp et al., 2024). The newer duration study found stronger evidence for symptom-independent neuroticism reduction in the second half of a 12-session course (Stumpp et al., 2026).
Together, these studies argue against the simplest version of the state-artifact explanation. They do not establish complete independence between symptoms and personality. Anxiety, depression, and neuroticism share variance, and change processes may be reciprocal. In the 2024 study, anxiety and neuroticism changes showed bidirectional relations.
A better model is dynamic: treatment can reduce disorder symptoms, alter emotional skills, change repeated patterns of appraisal and behavior, and shift trait self-reports over time. The question becomes how much of each change is state-dependent, how much persists, and which processes drive which outcomes.
Is the Unified Protocol better than standard CBT for neuroticism?
For neuroticism as measured in the 223-person trial, the UP produced a modestly larger reduction than the diagnosis-specific CBT protocols at week 16 (Sauer-Zavala et al., 2021). For the parent trial’s primary clinical outcome, UP and diagnosis-specific CBT were equivalent (Barlow et al., 2017). Both facts matter.
It would therefore be inaccurate to say that the UP is generally superior to CBT. The UP is itself a cognitive behavioral protocol. The appropriate comparison is between a transdiagnostic CBT package and diagnosis-specific CBT packages for particular outcomes. On disorder severity they performed similarly; on the neuroticism measure in the secondary analysis, the UP showed the larger reduction.
The neuroticism result is consistent with treatment design: the UP explicitly focuses on broad emotional vulnerabilities, while diagnosis-specific protocols concentrate on mechanisms and symptoms central to particular disorders. Replication across independent samples, measures, and settings remains important.
Is the Unified Protocol a treatment for high neuroticism by itself?
For the broader treatment question, including what therapy can change and what it cannot promise, see Therapy for High Neuroticism: What Treatment Can and Cannot Change.
The current evidence does not establish a clinical indication called “high neuroticism” that requires the Unified Protocol. Neuroticism is continuously distributed in the population. There is no universal DSM or ICD diagnosis of high neuroticism, and there is no universal cutoff across personality instruments at which therapy becomes necessary.
A person may score high on a validated neuroticism measure and function well. Another person may have clinically significant anxiety, depression, avoidance, or impairment with a less extreme trait score. Treatment decisions are made around distress, impairment, goals, diagnosed conditions when present, and an evidence-based clinical formulation—not around a personality percentile alone.
In a clinical setting, neuroticism can be useful as contextual information. It may help explain broad vulnerability across recurrent anxiety and mood symptoms or why several diagnoses share emotional mechanisms. The treatment target remains the person’s clinically relevant problems and processes.
This is one reason the article’s boundary matters: the Unified Protocol can change neuroticism-related trait measures in clinical samples, while that does not transform the protocol into generic personality optimization for the general population.
Does a lower neuroticism score mean someone is cured?
No. “Cure” is the wrong model for a dimensional personality trait. Neuroticism has no single disease threshold separating healthy from ill. Lower average neuroticism may be associated with less distress and lower statistical risk for some outcomes, but the trait also varies normally across people.
Even when treatment produces a durable reduction, the result should be described as trait change or increased emotional stability on a specified measure. If a psychiatric disorder is also present, remission or recovery refers to that disorder and must be evaluated with disorder-appropriate criteria and measures.
The language matters clinically. Saying “UP cured my neuroticism” merges a treatment effect, a personality construct, and a medical claim. A more accurate statement would identify what was measured: symptoms improved, emotional-response patterns changed, and a neuroticism score decreased over repeated assessments.
Does medication treat neuroticism?
Neuroticism itself is not a medication indication. Medication may be prescribed for a diagnosed psychiatric condition when clinically appropriate. Treatment of that condition can coincide with changes in personality-trait scores, especially when acute symptoms influence self-report, but a medication response does not convert neuroticism into a medical diagnosis.
The small UP-plus-SSRI trial is useful precisely because it separated a stable medication context from the added psychotherapy condition and measured several neuroticism-related constructs (Zemestani et al., 2022). It still should not be read as evidence that SSRIs “treat neuroticism” in the general population.
How neuroticism should be measured in UP research
Any claim about neuroticism change should name the instrument. The 223-person randomized analysis used EPQR-S Neuroticism. The 2024 repeated-measure study used NEO-FFI-N. These scales overlap in construct coverage but are not numerically interchangeable.
A raw score has no universal interpretation outside its scale. A percentile depends on a normative sample. A high score on one questionnaire cannot be mapped directly to a high score on another without validated crosswalks or comparable norming. Even “emotional stability” may be scored in the opposite direction from neuroticism, while BFI-2 uses Negative Emotionality as the domain label.
Measurement frequency also changes what can be learned. A pre/post design can show that scores differ after treatment. Weekly measurement can test trajectories, temporary fluctuations, time-lagged associations, and whether changes remain after controlling symptom variation. That is why the newer UP studies add information beyond the original randomized comparison.
For readers interpreting a personal result, the relevant questions are which instrument was used, how it was scored, which norms apply, how reliable the scale is, and whether a difference is larger than expected measurement noise. The English Hub’s Neuroticism Test guide explains these issues in detail.
What the evidence cannot yet establish
Current evidence does not establish that the Unified Protocol will lower neuroticism for every patient. Average treatment effects describe groups, not guaranteed individual responses. People differ in diagnosis, comorbidity, baseline trait level, treatment engagement, life context, medication use, and the mechanisms maintaining distress.
The evidence does not establish that a given reduction is permanent. Some studies include follow-up for clinical symptoms, but the neuroticism-specific literature remains smaller than the symptom-outcome literature. Durability of trait change across years, recurrence of symptoms, major life events, and different populations remains an active research question.
The evidence does not establish that neuroticism is the single causal mechanism through which the UP works. Skill changes, emotion regulation, exposure learning, cognitive flexibility, behavior, therapeutic alliance, expectations, and symptom processes can all contribute. Mediation requires stronger designs than a simple correlation between two changing variables.
The evidence also does not justify treating EPQR-S, NEO-FFI, BFI-2, IPIP, or other neuroticism scores as biomarkers. These are psychometric measures of a dimensional construct, not laboratory tests for a disease.
Finally, the strongest direct neuroticism trials have been conducted in adults with emotional disorders, often in specialized research settings. Generalization to children, adolescents, older adults, nonclinical high-neuroticism populations, culturally diverse settings, and severe or complex presentations should be based on direct evidence rather than assumption.
Who might discuss the Unified Protocol with a clinician?
The UP is most relevant when a person has clinically significant emotional problems that cross diagnostic boundaries or share strong patterns of emotional avoidance, reactivity, and maladaptive coping. Examples in research include anxiety disorders, depressive presentations, and related emotional disorders. Whether it is appropriate for a particular person depends on assessment, treatment availability, comorbidity, risk, goals, and clinician expertise.
A personality score can inform that discussion, but it should not replace it. If a person’s main concern is “I scored high in neuroticism,” the first step is to clarify whether there is meaningful distress, impairment, recurrent symptoms, or a treatment goal. If there is no clinical problem, a high trait score alone does not create a disorder that requires psychotherapy.
If there is a recognized condition, diagnosis-specific treatments may also be appropriate. The 2017 equivalence trial showed that UP and established single-disorder CBT protocols can produce comparable symptom outcomes for several anxiety disorders (Barlow et al., 2017). Choosing among evidence-based options is a clinical decision rather than a contest between personality labels.
Practical interpretation of treatment-related score change
Suppose a person begins therapy with an elevated neuroticism score and the score falls after treatment. The change can be meaningful, but interpretation should proceed in layers.
First, identify the measure. A 10-point change has different meaning on different scales. Second, examine symptoms and functioning separately. A trait score cannot substitute for anxiety, depression, OCD, trauma, or functioning measures. Third, consider timing. A rapid early shift may contain more state variance than a change that persists across repeated measurements. Fourth, consider whether the change remains after the acute episode resolves. Fifth, treat the result as evidence about that individual’s measured pattern, not proof of a universal causal mechanism.
The UP literature is valuable because researchers have begun to study exactly these layers rather than treating any pre/post personality difference as self-evident trait transformation.
Frequently asked questions
Does the Unified Protocol reduce neuroticism?
Randomized and longitudinal studies indicate that measured neuroticism can decrease during UP treatment. In a 223-person randomized analysis, UP produced lower neuroticism at week 16 than diagnosis-specific CBT or waitlist, and differences remained after controlling concurrent anxiety and depression changes. Newer repeated-measure studies support a distinction between earlier state-like change and later trait-like change.
Is neuroticism a mental disorder?
No. Neuroticism is a dimensional personality trait. It is associated with transdiagnostic risk for several mental-health problems, but a high trait score does not diagnose any disorder.
Was neuroticism actually measured in the major randomized trial?
Yes. The 223-person analysis used the 12-item Neuroticism subscale of the Eysenck Personality Questionnaire Revised–Short Form, or EPQR-S. The 2024 repeated-measure study used the 12-item NEO-FFI Neuroticism subscale. Results from those instruments should not be converted directly into scores on other tests.
Is the Unified Protocol just CBT?
It is a cognitive behavioral treatment, but it is organized transdiagnostically. Rather than using a separate protocol for each diagnosis, it teaches a common set of emotion-focused skills intended to address processes shared across emotional disorders.
Is the Unified Protocol better than diagnosis-specific CBT?
On the primary clinical outcome in the landmark anxiety-disorder trial, UP and diagnosis-specific CBT were equivalent. In the secondary neuroticism analysis, UP produced a larger reduction on the neuroticism measure. The appropriate conclusion depends on which outcome is being discussed.
How quickly can neuroticism change in UP?
One repeated-measure study detected state-level change by session 6 and trait-level change by session 12. A later randomized duration study found that symptom-independent neuroticism reductions were clearer during sessions 7 through 12 than during the first six sessions. These studies do not create a universal session threshold for every patient.
Does symptom improvement prove personality change?
No. Symptoms and trait self-reports overlap, so improvement in anxiety or depression can alter neuroticism scores. Stronger evidence for trait change comes from repeated measurement, symptom controls, temporal analyses, and persistence over time.
Can a person have high neuroticism without needing treatment?
Yes. Neuroticism is continuously distributed, and high scores do not automatically mean disorder or impairment. Treatment is guided by clinically meaningful distress, impairment, goals, and recognized conditions—not by a trait score alone.
Can the Unified Protocol be used simply to optimize personality?
The current evidence base is centered on treatment-seeking people with emotional disorders. Research showing neuroticism change in those samples does not establish UP as a generic personality-optimization intervention for nonclinical populations.
Does the UP cure neuroticism?
No. Cure language does not fit a dimensional personality trait. Research supports possible reductions in measured neuroticism and increases in emotional stability, while clinical recovery refers to symptoms, functioning, and diagnosed conditions.
Does medication lower neuroticism?
Neuroticism is not itself a medication indication. Medication can treat diagnosed conditions and may coincide with changes in trait self-report. Studies combining UP with stable SSRI treatment have reported improvement in several neuroticism-related processes, but those processes should not be collapsed into a generic claim that medication treats neuroticism.
What is the best way to interpret a neuroticism score after therapy?
Use the same validated instrument when possible, check its scoring method and norms, compare the size of change with measurement reliability, and interpret the result alongside symptoms, functioning, and repeated assessments. A single raw score or percentile cannot establish durable personality change.
Conclusion
The Unified Protocol provides one of the clearest examples of modern psychotherapy research treating neuroticism as a modifiable dimensional vulnerability rather than as a fixed essence or a diagnosis. In the largest direct randomized analysis, UP produced a modest but significant advantage over diagnosis-specific CBT and waitlist on EPQR-S neuroticism, and the difference remained after adjustment for concurrent anxiety and depression changes. Subsequent repeated-measure work using NEO-FFI-N has sharpened the picture by showing that early change can be state-like while later change across a fuller treatment course more closely resembles trait-level change.
The evidence therefore supports a precise conclusion: neuroticism-related personality measures can change during Unified Protocol treatment in adults with emotional disorders, and some of that change appears to extend beyond immediate symptom fluctuation. The evidence supports neither a universal promise of personality change nor a claim that high neuroticism is an illness requiring treatment. The clinically meaningful target remains the person’s emotional problems, functioning, and goals, measured with tools appropriate to each construct.
Related Articles
References
Barlow, D. H., Farchione, T. J., Bullis, J. R., Gallagher, M. W., Murray-Latin, H., Sauer-Zavala, S., Bentley, K. H., Thompson-Hollands, J., Conklin, L. R., Boswell, J. F., Ametaj, A., Carl, J. R., Boettcher, H. T., & Cassiello-Robbins, C. (2017). The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with diagnosis-specific protocols for anxiety disorders: A randomized clinical trial. JAMA Psychiatry, 74(9), 875–884. https://doi.org/10.1001/jamapsychiatry.2017.2164
Carlucci, L., Saggino, A., & Balsamo, M. (2021). On the efficacy of the Unified Protocol for transdiagnostic treatment of emotional disorders: A systematic review and meta-analysis. Clinical Psychology Review, 87, 101999. https://doi.org/10.1016/j.cpr.2021.101999
Farchione, T. J., Fairholme, C. P., Ellard, K. K., Boisseau, C. L., Thompson-Hollands, J., Carl, J. R., Gallagher, M. W., & Barlow, D. H. (2012). Unified protocol for transdiagnostic treatment of emotional disorders: A randomized controlled trial. Behavior Therapy, 43(3), 666–678. https://pubmed.ncbi.nlm.nih.gov/22697453/
Farchione, T. J., Sauer-Zavala, S., & Barlow, D. H. (2024). State of the science: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. Behavior Therapy. https://pubmed.ncbi.nlm.nih.gov/39443061/
Roberts, B. W., Luo, J., Briley, D. A., Chow, P. I., Su, R., & Hill, P. L. (2017). A systematic review of personality trait change through intervention. Psychological Bulletin, 143(2), 117–141. https://doi.org/10.1037/bul0000088
Sakiris, N., & Berle, D. (2019). A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based intervention. Clinical Psychology Review, 72, 101751. https://doi.org/10.1016/j.cpr.2019.101751
Sauer-Zavala, S., Fournier, J. C., Steele, S. J., Woods, B. K., Wang, M., Farchione, T. J., & Barlow, D. H. (2021). Does the Unified Protocol really change neuroticism? Results from a randomized trial. Psychological Medicine, 51(14), 2378–2387. https://doi.org/10.1017/S0033291720000975
Sauer-Zavala, S., Rosellini, A. J., Bentley, K. H., Ametaj, A. A., Boswell, J. F., Cassiello-Robbins, C., Tirpak, J. W., Farchione, T. J., & Barlow, D. H. (2021). Skill acquisition during transdiagnostic treatment with the Unified Protocol. Behavior Therapy, 52(6), 1325–1338. https://doi.org/10.1016/j.beth.2021.03.001
Stumpp, N. E., Southward, M. W., & Sauer-Zavala, S. (2024). Assessing theories of state and trait change in neuroticism and symptom improvement in the Unified Protocol. Behavior Therapy, 55(1), 93–105. https://doi.org/10.1016/j.beth.2023.05.005
Stumpp, N. E., Southward, M. W., Hines, A., Kushner, M. L., Schäuffele, C., Fruhbauerova, M., Bridges, E., Rahman, A., & Sauer-Zavala, S. (2026). When and under what circumstances does neuroticism change in the Unified Protocol? Psychotherapy Research, 36(4), 785–796. https://doi.org/10.1080/10503307.2025.2521779
Zemestani, M., Ommati, P., Rezaei, F., & Gallagher, M. W. (2022). Changes in neuroticism-related constructs over the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in patients on an optimal dose of SSRI. Personality Disorders: Theory, Research, and Treatment, 13(2), 171–181. https://doi.org/10.1037/per0000482